Business Wire

Cvent Exceeds 3,000 European Customers and Announces New European Office

Del

Cvent. Inc., a global leader in cloud-based meetings, events, hospitality and travel technology, today announced plans to open their first location in Germany. It will be their third European office. The new location will support increased demand in the region as well as provide localised support for current Cvent customers including: Adidas, SCHOTT AG, PROSKE Group, MERCK KG auf Aktian, Travel Industry Club, and Lufthansa City Center International. The announcement highlights Cvent’s ongoing expansion in the European marketplace.

“Europe has been dominating the MICE industry with a 42% market share* and the UK and Germany are the biggest source markets for that group business. Through our Cvent Supplier Network, we have seen a 23% increase in request for proposal (RFP) volume year over year in the EMEA region that clearly reflects the strong European MICE market,” said David Chalmers, Senior Marketing Director, Cvent Europe. “There has been tremendous growth in demand for meetings and events technology, especially in Germany where 31%* of business trips can be attributed to meetings and events, and digitisation is key to industry growth. Our customers in the region realise they need to harness the power of technology to demonstrate return on investment for their events, as well as capitalise on new business opportunities and leads.”

What Customers Are Saying:

“The biggest advantage of using Cvent’s solutions is that they really enable us to relieve our quite small team and redefine our main focus in the event planning process,” said David Willmes of SCHOTT AG. “Administrative tasks can be completed in much less time or even fully automated with Cvent’s software.”

"When I first discovered it [the Cvent Platform], it was a revelation to me. When you go from doing things manually to have a system like that in place, it really is the difference between night and day," said Sarah Byrne, Director of Mosaic Events.

Earlier this year, Cvent unveiled their new European headquarters based in Paddington, London. Cvent’s previous office, located in central London, did not have the capacity to accommodate Cvent’s growth and expansion in the region.

“This is a very exciting time for the company. We are rapidly expanding our customer base in the UK and across Europe,” said Cvent Founder and CEO Reggie Aggarwal. “Adding a third European location in Germany ensures we have the right people on the ground to provide local support and to respond to our customers’ needs and heightens our ability to provide best-in-class service.”

The announcement comes after recent news regarding the company’s strongest year yet which saw the addition of thousands of new customers signed internationally. Across the globe, more than 3,000 employees now work for the company and Cvent expects to hire 1,000 more people by the end of 2018 to help fuel future growth. To support the increased headcount, Cvent will add more than 140,000 square feet of office space worldwide. Cvent also plans to open an office in Dubai later this year in order meet demand in the Middle East and Africa for its event and hospitality cloud platforms.

*Allied Market Research, Jan 2018

*Meeting and Event Barometer, 2017/2018

www.cvent.co.uk

Notes to Editor

About Cvent

Cvent, Inc. is a leading cloud-based enterprise event management company with more than 25,000 customers, 300,000 users, and 3,000 employees worldwide. Cvent offers software solutions to event planners for online event registration, venue selection, event management, mobile apps for events, email marketing, and web surveys. Cvent provides hoteliers with an integrated platform, enabling properties to increase group business demand through targeted advertising and improve conversion through proprietary demand management and business intelligence solutions. Cvent solutions optimise the entire event management value chain and have enabled clients around the world to manage hundreds of thousands of meetings and events. For more information, please visit Cvent.com/UK or connect with us on Facebook, Twitter or LinkedIn.

Contact information

For Cvent, Inc.
Sam Pepper
sam.pepper@spotlightcoms.com
or
Sharon Coleshill, +44 (0) 208 334 4005
sharon.coleshill@spotlightcoms.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00Pressemelding

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00Pressemelding

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27Pressemelding

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00Pressemelding

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 10:11Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 10:06Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo